Abstract: A pharmaceutical composition and a health functional food composition for preventing, treating, or improving muscular diseases have licorice extract or a fraction thereof, or a compound isolated therefrom or a pharmaceutically acceptable salt thereof, as an active ingredient. The licorice extract or a fraction thereof, the compound or salt thereof induce the myoblasts proliferation and promote the differentiation into myotubes, and since the licorice extract or a fraction thereof, the compound or salt thereof has an excellent effect on regenerating damaged muscles, various muscle diseases are effectively prevented, improved or treated using the composition.

Abstract: The present invention relates to a novel peptide for promoting the proliferation and differentiation of myoblasts or inhibiting the proliferation and differentiation of preadipocytes, and use thereof. A novel peptide is designed on the basis of an amino acid site, from among parts of a myostatin (MSTN) protein, binding to a fibromodulin protein, and then: C2C12 cells, which are a mouse myoblast cell line, are treated with the peptide so that cell proliferation and differentiation, muscle regeneration and the like are observed, and it has been identified that the proliferation and differentiation of myoblasts and the regeneration of muscles increase after the treatment with the designed peptide; and 3T3L1 cells, which are mouse preadipocytes, are treated with the peptide so that cell proliferation, fat differentiation, and the like are observed, and it has been identified that the proliferation of preadipocytes and fat differentiation decrease after the treatment with the peptide.

Abstract: The present invention relates to: a novel peptide that promotes the proliferation and differentiation of myoblasts; and a use thereof. The novel peptide was designed around amino acid sites, binding to a fibromodulin protein, in a portion of myostatin (MSTN) proteins, and then cells of C2C12, which is a mouse myoblast line, were treated with the novel peptide to observe the proliferation and differentiation of the cells and the regeneration of muscle, and it was confirmed that the proliferation and differentiation of myoblasts and the regeneration of muscle increases after the myoblasts are treated with the designed peptide.

Abstract: The present invention relates to a method and system for evaluating insulation and lithium ion conductivity characteristics of a separator for an electrochemical device, in which insulation and lithium ion conductivity characteristics are evaluated while a separator-containing measurement object to be tested and an electrochemical device are made to face each other, and thus, the insulation and lithium ion conductivity characteristics of the separator can be evaluated by reflecting temperature and pressure changes and the like according to the actual operation state of the electrochemical device.

Abstract: The present invention relates to a novel peptide having various physiological activities and use thereof. The novel peptide according to the present invention induces an increase in joint components in chondrocytes, increases the cartilage differentiation of mesenchymal stem cells and the production of extracellular matrix, suppresses an increase in inflammatory cytokines or inflammatory proteins, and can also suppress the differentiation and formation of osteoclasts, and thus can be effectively used as an active ingredient of a pharmaceutical composition for regenerating cartilage or preventing or treating an inflammatory disease or osteoporosis, or a health functional food for ameliorating the symptoms.

Abstract: The present invention relates to a novel Bifidobacterium bifidum MG731 strain and a composition for preventing or treating cancers, comprising the same. Specifically, the Bifidobacterium bifidum MG731 strain of the present invention has effects of inhibiting the proliferation of cancer cells, decreasing the mobility of cancer cells, inhibiting the neoangiogenesis, and increasing the anticancer immune response as well as reducing the expression of inflammatory factors, thereby having effects of preventing or treating cancers or inflammatory diseases. In addition, when used in combination with an anticancer chemotherapeutic agent or an anticancer immunotherapeutic agent, the Bifidobacterium bifidum MG731 strain of the present invention exhibits a better anticancer effect. In addition, the present invention relates to a novel Lactococcus lactis GEN3033 strain and a composition for preventing or treating cancers, comprising the same.

Abstract: Provided are a benzoindazolone compound, or a pharmaceutically acceptable salt, hydrate, solvate, enantiomer, diasteromer, tautomer or prodrug thereof; and an intermediate thereof, wherein the compound is used as a substrate for NQO1 to facilitate a redox reaction of NQO1, and thus is expected to be developable as a medicine for preventing or treating inflammatory diseases.

Abstract: A method of quantitatively analyzing a carbon based hybrid negative electrode including the steps of preparing a secondary battery including a carbon based hybrid negative electrode, where the carbon based hybrid negative electrode comprises a carbon based negative electrode active material and a non-carbon based negative electrode active material, measuring a lattice d-spacing of the carbon based negative electrode active material in the carbon based hybrid negative electrode during charging/discharging of the secondary battery using an X-ray diffractometer and then plotting a graph of a change in lattice d-spacing value as a function of charge/discharge capacity, detecting an inflection point of a slope of the graph during discharging; and then, quantifying capacity contribution of the carbon based negative electrode active material and the non-carbon based negative electrode active material in the total discharge capacity of the secondary battery by the inflection point of the slope of the graph.

Abstract: The present invention relates to a method for manufacturing a secondary battery and a secondary battery. The method for manufacturing the secondary battery comprises an accommodation step of accommodating an electrode assembly in an accommodation part of a battery case, a vent membrane mounting step of mounting a vent membrane on a discharge hole, which passes between the inside and outside of the battery case, in the battery case, and a case sealing step of sealing the battery case, wherein the vent membrane allows only a gas to pass through the discharge hole of the battery case, but blocks a liquid.

Abstract: The present invention provides an electrode assembly in which a negative electrode coated with a negative electrode active material on a surface of a negative electrode collector, a separator, and a positive electrode coated with a positive electrode active material on a surface of a positive electrode collector are repeatedly laminated, the electrode assembly comprising: monocells in which the positive electrode, the separator, the negative electrode, and the separator are laminated, wherein at least two or more monocells are laminated, wherein, in any one of the monocells, an expansion part extending lengthily to one side is formed on the separators, and the expansion part of the separator surrounds the monocells laminated to be disposed at the outermost layers to fix the laminated monocells.

Abstract: Disclosed herein provides a battery module configured to recognize the time when the volume change of a battery cell converts again from a stagnant state to an increasing state as a gas venting risk point, a battery pack, and a method for detecting a gas venting risk point. The present invention can recognize the risk of gas venting immediately before a gap is formed in a sealing part of a pouch-type battery cell, thereby having an effect of improving the safety of a battery module and a battery pack to which particularly large-capacity battery cells are applied.

Abstract: A negative electrode including: a current collector; a first negative electrode active material layer positioned on at least one surface of the current collector for a negative electrode and containing a first carbonaceous active material; and a second negative electrode active material layer positioned on a surface of the first negative electrode active material layer and containing a silicon-based active material and carbon nanotubes. A lithium secondary battery including the negative electrode is also disclosed.

Abstract: The present invention provides an electrode assembly in which a negative electrode coated with a negative electrode active material on a surface of a negative electrode collector, a separator, and a positive electrode coated with a positive electrode active material on a surface of a positive electrode collector are repeatedly laminated, the electrode assembly comprising: monocells in which the positive electrode, the separator, the negative electrode, and the separator are laminated, wherein at least two or more monocells are laminated, wherein, in any one of the monocells, an expansion part extending lengthily to one side is formed on the separators, and the expansion part of the separator surrounds the monocells laminated to be disposed at the outermost layers to fix the laminated monocells.

Abstract: A battery management system includes a displacement sensor configured to detect a displacement of a cell group including a plurality of battery cells connected in parallel, and a control unit. The control unit is configured to record the displacement of the cell group at a predetermined time interval for a first diagnosis period from a first time point to a second time point during charging of the cell group. The control unit is configured to determine a first displacement curve from a history of the displacement over the first diagnosis period. The control unit is configured to determine whether the plurality of battery cells is nonuniformly degraded based on the first displacement curve.

Abstract: Provided is a method of diagnosing the degradation of a lithium secondary battery in a non-destructive manner without disassembling the battery, which includes: obtaining, from X-ray diffraction (XRD) data obtained during first charging of the lithium secondary battery, a first graph showing the change of the c-axis d-spacing value of the layered positive electrode active material according to the number of moles of lithium ions deintercalated from the layered positive electrode active material during the charging; obtaining, from XRD data obtained during second charging of the lithium secondary battery, a second graph showing the change of the c-axis d-spacing value of the layered positive electrode active material according to the number of moles of lithium ions deintercalated from the layered positive electrode active material during the charging; and classifying a cause of degradation of the secondary battery by comparing the first graph and the second graph.

Abstract: The present invention provides an electrode assembly in which a negative electrode coated with a negative electrode active material on a surface of a negative electrode collector, a separator, and a positive electrode coated with a positive electrode active material on a surface of a positive electrode collector are repeatedly laminated, the electrode assembly comprising: monocells in which the positive electrode, the separator, the negative electrode, and the separator are laminated, wherein at least two or more monocells are laminated, wherein, in any one of the monocells, an expansion part extending lengthily to one side is formed on the separators, and the expansion part of the separator surrounds the monocells laminated to be disposed at the outermost layers to fix the laminated monocells.

Abstract: A negative electrode including: a current collector; a first negative electrode active material layer positioned on at least one surface of the current collector for a negative electrode and containing a first carbonaceous active material; and a second negative electrode active material layer positioned on a surface of the first negative electrode active material layer and containing a silicon-based active material and carbon nanotubes. A lithium secondary battery including the negative electrode is also disclosed.

Abstract: A substrate transfer unit is provided. The substrate transfer unit includes: a rail part having a length in a horizontal direction; a vertical part moving along the rail part, guiding the vertical movement of a robot, which transfers a substrate, and having, formed therein, first flow paths that a fluid is introduced into and passes through; main duct parts having, formed therein, second flow paths which communicate with the first flow paths, having first end portions connected to the vertical part, and including outlets, which are formed at second end portions of the main duct parts and face a bottom surface of the index module, and through holes, which are formed on one or both sides of each of the second end portions; and auxiliary duct parts surrounding the through holes at the second end portions of the main duct parts and having, formed therein, expansion spaces which communicate with the second flow paths.

Abstract: A pouch and a secondary battery including the pouch, and a method for manufacturing the same are described. The method for manufacturing the secondary battery includes: a hole formation process of forming a degassing hole in an aluminum sheet; and a lamination process of laminating a polymer layer on the aluminum sheet to manufacture a pouch; an accommodation process of accommodating an electrode assembly in the pouch; and a sealing process of sealing an outer circumferential surface of the pouch.

Abstract: Provided are an imidazoquinoline or benzoindazolone compound or a pharmaceutically acceptable salt, hydrate, solvate, enantiomer, diastereomer, tautomer or precursor drug thereof; a use thereof for preventing and treating an inflammatory disease; and an intermediate for preparing same, where the compound is used as a substrate of NQO1 to activate the oxidation-reduction of NQO1, thus making it possible to prevent the expression and activity of inflammatory cytokines, and as such, can be used for preventing or treating diseases associated with NQO1 activity.